(MedPage Today) — Nivolumab (Opdivo) plus ipilimumab (Yervoy) showed significant activity in patients with advanced gynecologic clear cell carcinomas, according to results from a phase II nonrandomized trial.
Among 26 evaluable patients with…
Source link : https://www.medpagetoday.com/hematologyoncology/ovariancancer/116371
Author :
Publish date : 2025-07-03 15:00:00
Copyright for syndicated content belongs to the linked Source.
